LAS 41007

Drug Profile

LAS 41007

Alternative Names: LAS41007

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Almirall S.A.
  • Class Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Actinic keratosis

Most Recent Events

  • 30 Jul 2012 Discontinued - Phase-III for Actinic keratosis in Germany (Topical)
  • 23 Jul 2012 Almirall completes a phase III trial in Actinic keratosis in Germany (NCT01265602)
  • 30 Nov 2010 Phase-III clinical trials in Actinic keratosis in Germany (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top